Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), taking place May 12-16, 2026, in Padua, Italy. The AEPC, founded in 1963, is the world’s largest association in congenital cardiology, with over 1,000 specialists from 32 European countries and beyond, all dedicated to advancing the practice of congenital and paediatric cardiology and improving outcomes for patients with heart disease.
This year’s meeting, hosted by the University of Padova, features a scientific program centered on advanced cardiovascular imaging and artificial intelligence—areas where Ventripoint is making significant clinical progress. Ventripoint will exhibit alongside its European distributor, AngioPro, to engage with clinicians from the global congenital cardiology community. A key focus will be the use of VMS+™ to support monitoring of cardiac function over time in congenital heart disease (CHD) patients. This approach aligns with the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, which identify CHD as a lifelong chronic condition requiring structured follow-up and affirm echocardiography as the key modality for longitudinal assessment of ventricular function (Baumgartner et al., European Heart Journal, 2021).
Ventripoint’s priority for 2026 is accelerating the integration of VMS+™ into routine clinical practice and building better care pathways for CHD patients. The latest release, VMS+™ 4.0, streamlines workflows, reduces assessment time, and makes advanced cardiac analysis accessible at the point of care. At the first echocardiogram, VMS+™ provides accurate volumetric cardiac measurements equivalent to MRI, supporting clinical decision-making and effective patient management throughout a lifetime of care.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI—giving clinicians the confidence they need to manage their patients at every stage of life.”
Ventripoint is an industry leader in applying artificial intelligence to echocardiography. Its VMS+™ product family, powered by proprietary KBR technology, delivers volumetric cardiac measurements with accuracy equivalent to MRI, providing a gold-standard alternative for cardiologists. VMS+™ is compatible with ultrasound systems from all major vendors and holds regulatory approvals in the U.S., Europe, and Canada.
This news release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on expectations and assumptions that the Company believes are reasonable but involve inherent risks and uncertainties. Factors that could cause actual results to differ materially are described in the Company’s most recent annual management’s discussion and analysis available on SEDAR at www.sedar.com. The Company undertakes no obligation to update forward-looking statements except as required by law.
